Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04690751 · ClinicalTrials.gov registry record · Phase 1
Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet
A Phase 1 study, sponsored by SK Life Science.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT04690751 is a Phase 1 study that has completed, run by SK Life Science. The registered enrollment target is 28 participants.
The verdict
NCT04690751, a Phase 1 study, has completed, sponsored by SK Life Science.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is designed to evaluate the relative bioavailability, or the degree and rate at which the drug is absorbed by the body of two cenobamate formulations (200 mg Oral Suspension and a 200 mg Oral Tablet) and to assess the effect of food on the oral bioavailability of the 200 mg Oral Suspension. This study will also look at the safety and tolerability of the oral suspension and the oral tablet under both fasted and fed conditions.
Interventions
- DRUG Cenobamate 200Mg Tab Fasted
- DRUG Cenobamate Oral Suspension Fed
- DRUG Cenobomate Oral Suspension Fasted
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-12-21 |
| Est. Completion | 2021-05-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04690751
The ClinicalTrials.gov registry entry for NCT04690751 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SK Life Science, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cenobamate 200Mg Tab Fasted is the first listed.
NCT04690751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04690751 about?
NCT04690751 is a clinical study titled "Bioavailability and Food Effect Study of Cenobamate as an Oral Suspension and Tablet". This study is designed to evaluate the relative bioavailability, or the degree and rate at which the drug is absorbed by the body of two cenobamate formulations (200 mg Oral Suspension and a 200 mg Oral Tablet) and to assess the effect of food on the oral bioavailability of the 200 mg Oral Suspensio...
What is the current status of trial NCT04690751?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2020-12-21. Estimated completion is 2021-05-17.
What interventions are being tested in trial NCT04690751?
The interventions under investigation include: Cenobamate 200Mg Tab Fasted (DRUG), Cenobamate Oral Suspension Fed (DRUG), Cenobomate Oral Suspension Fasted (DRUG).
Who is sponsoring clinical trial NCT04690751?
This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.